ALT NASDAQ
Altimmune, Inc.
1W: +0.3%
1M: -15.6%
3M: -33.1%
YTD: -37.5%
1Y: -36.7%
3Y: -29.2%
5Y: -77.3%
$2.90
-0.03 (-1.02%)
Weekly Expected Move ±12.0%
$2
$3
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (81)
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Altimmune (ALT) Q1 2026 Earnings Transcript
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Here are the major earnings before the open Wednesday
Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
12 Health Care Stocks Moving In Thursday's Intraday Session
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
Why Is Altimmune Stock Falling Today?
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Biggest stock movers Thursday: IBM, QS, NOW, and more
Altimmune prices $225M public offering of securities
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
12 Health Care Stocks Moving In Wednesday's After-Market Session
Altimmune launches proposed public offering to fund late-stage trial
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Brokerages
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
ALT Pemvidutide Explained: What Makes It Different in MASH
What is HC Wainwright’s Estimate for Altimmune Q1 Earnings?
Altimmune a new buy at Truist on pemvidutide promise
Q4 Earnings Forecast for Altimmune Issued By HC Wainwright
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Hold” by Analysts
Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances
Altimmune to start late-stage trial for MASH candidate this year
Altimmune (ALT) Q4 2025 Earnings Call Transcript
Altimmune: Q4 Earnings Insights
Altimmune GAAP EPS of -$0.27 misses by $0.03, revenue of $0.03M beats by $0.03M
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Earnings Scheduled For March 5, 2026
Here are the major earnings before the open Thursday
Altimmune Q4 2025 Earnings Preview
What to Expect from Altimmune's Earnings
Altimmune to Participate in Upcoming Investor Conferences
Earnings week ahead: AVGO, CRWD, PLUG, COST, TGT, MRVL, JD, KR, and more
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide
ALT5 Sigma Corporation Issues Stockholder Letter and Provides Corporate Update
ALT5 Sigma Corporation Appoints Dr. Adel Elmessiry to Board of Directors
Altimmune (NASDAQ:ALT) Shares Up 7.2% – Time to Buy?
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
ALT5 Sigma Corporation to Join Global Leaders at Inaugural World Liberty Forum at Mar-a-Lago
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
ALT5 Sigma Corporation Launches ALT5 AI to Power the Next Era of Enterprise AI—Where Crypto, Compliance and AI Payment Rails Converge
ALT5 Sigma Corporation Restores Compliance with Nasdaq Periodic Filing Requirements
ALT5 Sigma Corporation Reports Q3 2025 Financial Results and Significant Milestones
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
ALT5 Sigma Expects to File its Quarterly Report on Form 10-Q for the Third Quarter 2025 in the Coming Days
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
ALT5 Sigma Congratulates Strategic Partner World Liberty Financial on USD1 Stablecoin Surpassing $3 Billion Market Capitalization
ALT5 INVESTIGATION: Investigation Launched into ALT5 Sigma Corporation, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - ALTS
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Acquires 12,500 Shares of Stock
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Analysts
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
ALT5 Sigma Corporation Issues Stockholder Letter From CEO Tony Isaac
ALT5 INVESTIGATION ALERT: Investigation Launched into ALT5 Sigma Corporation, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - ALTS
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
ALT5 Sigma Corporation Provides Strategic Overview of $WLFI Treasury Strategy, USD1 Stablecoin Utility and Its Relevance to the Company's Future Payment Infrastructure
ALT5 Sigma Corporation Provides Corporate Update
ALT5 Sigma Receives Expected Nasdaq Notification Regarding Late Filing of Form 10-Q
Altimmune Announces CEO Transition and Succession Plan
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know
Investors Purchase High Volume of Altimmune Call Options (NASDAQ:ALT)
Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript